Current Trial - Enrolling
To evaluate the effects of GB001 as maintenance therapy in adults with moderate to severe asthma.
- 18-75 years old
- medium-high dose ICS plus additional controller
- ≥1 asthma exacerbations requiring treatment w/ systemic corticosteroids in the 12 months
Clinical and Population Research